SynthesisScientific reports2026
Clinicopathological significance of Gli1 expression in hepatocellular carcinoma: a meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This meta-analysis assessed the clinicopathological significance of GLI1 in hepatocellular carcinoma (HCC). We systematically searched PubMed, Web of Science, Embase, Cochrane Library, Wan Fang, and CNKI for studies through October 2025. Studies assessing GLI1 by immunohistochemistry in HCC tissue and reporting its clinicopathological correlations were included. Study quality was evaluated using the Newcastle-Ottawa Scale. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Publication bias and sensitivity analyses were performed, and subgroup analyses were conducted when > 4 studies were available. Analysis of ten studies (n = 974) showed significant GLI1 upregulation in HCC versus non-tumorous tissues (OR = 7.06, 95% CI 3.21-15.54, P < 0.0001). Elevated GLI1 was associated with intrahepatic metastasis (OR = 2.51, 95% CI 1.42-4.43, P = 0.002), vascular invasion (OR = 2.98, 95% CI 1.64-5.42, P < 0.001), hepatitis B virus (HBV) infection (OR = 2.32, 95% CI 1.28-4.20, P = 0.006). The significance of advanced pTNM stage (OR = 3.03, 95% CI 1.29-7.10, P = 0.011) disappeared after adjusting for publication bias (adjusted OR = 1.94, 95% CI 0.85-4.40). No significant associations were found with patient age, liver cirrhosis, serum AFP level, and tumor size. Findings are based on observational studies with heterogeneity in GLI1 assessment; evidence certainty for several outcomes is low or very low. These findings support the hypothesis that GLI1 might be involved in aggressive HCC phenotypes and warrant its investigation in future, standardized prospective studies to assess its potential clinical utility.Trial registration: The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD42024500731).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.